Samsung Bioepis Inks Settlement and Licensing Deal with Regeneron and Bayer for Commercialization of SB15 (Biosimilar, Eylea) 

Shots: 

• Samsung Bioepis has signed a settlement and license agreement with Regeneron and Bayer for the commercialization of SB15, a biosimilar version of Eylea 2 mg (aflibercept 40 mg/mL solution), in markets excluding the US and Canada  

• The agreement allows Samsung Bioepis to launch SB15 in the UK from Jan 2026, across the EU from Apr 2026, and in other settled markets (excluding Korea) from May 2026, with the remaining terms kept confidential  

• Samsung Bioepis’ OPUVIZ™ (aflibercept 40 mg/mL) received approval from the European Commission in Nov 2024 and the UK MHRA in Apr 2025 

Ref: Samsung Bioepis | Image: Samsung Bioepis, Regeneron & Bayer |  Press Release 

Related News: Alvotech Inks Settlement and Licensing Deal with Regeneron and Bayer for Worldwide Commercialization for its Biosimilar to Eylea 

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com